Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine
Atzumi is the first and only product utilizing the SMART (Simple MucoAdhesive Release Technology) platform which combines a proprietary advanced powder and device technology to simplify delivery of DHE.
In clinical studies, Atzumi administration provided rapid and sustained DHE concentrations with low variability.
DURHAM, N.C., April 30, 2025 /PRNewswire/ — Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to bringing novel treatments to people who suffer from migraine and other debilitating conditions, and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395), today announced that the U.S. Food and Drug Administration (FDA) has approved a 505(b)(2) New Drug Application (NDA) for Atzumi™(dihydroergotamine (DHE)) nasal powder for the acute treatment of migraine with or without aura in adults. Atzumi was previously known as STS101.
Migraine is a neurological disorder that is thought to be the result of temporary changes in the chemicals, nerves and blood vessels in the brain, with symptoms that are often incapacitating. According to the American Migraine Foundation, approximately 40 million Americans live with migraine. It is the second leading cause of disability worldwide in terms of time lost to disability and most common cause of disability among young women.
'The approval of Atzumi is a milestone to celebrate, providing a new option for the acute treatment of migraine combining long-proven benefits of DHE with a patient-friendly and easy-to-use delivery system developed based on SNBL's novel intranasal drug delivery platform technology,' said Dr. Ryoichi Nagata, President and CEO of Satsuma. 'We believe that Atzumi will contribute to improving the quality of life of patients struggling for relief from these highly disabling problems.'
'DHE plays a unique clinical role in the acute treatment of migraine, providing patients long lasting effects and the unique ability to provide benefit even when taken late in a migraine attack. The convenience of Atzumi, the only DHE nasal powder, will offer patients ease of use combined with the important known DHE clinical advantages', said Dr. Stewart J. Tepper, M.D., Vice President of the New England Institute for Neurology and Headache in Stamford, Connecticut.
About Atzumi
Atzumi is a proprietary drug device product incorporating both Satsuma's advanced nasal powder formulation of dihydroergotamine (DHE) administered via its unique nasal delivery device. The product is designed to provide patients an easy-to-use and easy-to-carry treatment option.
The FDA approval for Atzumi is based on two clinical studies (Phase 1 PK trial and ASCEND Phase 3 open-label, long-term safety trial), which demonstrated fast absorption, rapid achievement of high DHE plasma concentrations, and sustained DHE plasma levels over time as well as safety and tolerability in subjects with migraine.
About Dihydroergotamine (DHE)
Since its approval in 1946, DHE has long been recommended in published migraine treatment guidelines as a first-line acute treatment option for migraine and has significant advantages versus other anti-migraine treatments for many patients. However, disadvantages of current DHE liquid nasal spray and injectable products, including invasive and burdensome administration and/or sub-optimal clinical performance, have limited the widespread use of DHE.
IMPORTANT SAFETY INFORMATION
WARNING: PERIPHERAL ISCHEMIA FOLLOWING COADMINISTRATION WITH STRONG CYP3A4 INHIBITORS
Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with strong CYP3A4 inhibitors. Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of Atzumi with strong CYP3A4 inhibitors is contraindicated.
Indication
Atzumi is an ergotamine derivative indicated for the acute treatment of migraine with or without aura in adults.
Limitations of Use
Atzumi is not indicated for the preventive treatment of migraine or for the management of hemiplegic migraine or migraine with brainstem aura.
Contraindications
Atzumi is not recommended in patients with:
Concomitant use of strong CYP3A4 inhibitors
Ischemic heart disease or coronary artery vasospasm
Uncontrolled hypertension, peripheral arterial diseases, sepsis, following vascular surgery, or severe hepatic or renal impairment
Hypersensitivity to ergot alkaloids
Concomitant use of other 5-HT₁ agonists or ergotamine-containing or ergot-type medication within 24 hours
Concomitant use of peripheral and central vasoconstrictors
Warnings and Precautions
Atzumi may cause:
Cardiac events: Cardiac events in patients with risk factors of coronary artery diseases: Consider administration of the first dose of Atzumi under medical supervision (including the use of an electrocardiogram)
Cerebrovascular events: Cerebrovascular events (eg, cerebral hemorrhage, subarachnoid hemorrhage, and stroke) have been reported, particularly with dihydroergotamine mesylate injection
Vasospasm/elevated blood pressure: Dihydroergotamine may cause vasospasm or elevation in blood pressure
Medication overuse headache: Detoxification may be necessary
Preterm labor: Advise pregnant women of the risk
Fibrotic complications: Rare cases have been reported following prolonged daily use of dihydroergotamine mesylate. Administration of Atzumi should not exceed the dosing guidelines or be used for chronic daily administration
Local irritation: Local irritation has been reported following administration of Atzumi
Most Common Adverse Reactions
Most common adverse reactions (incidence >1%) were rhinitis, nausea, altered sense of taste, application site reaction, dizziness, vomiting, somnolence, pharyngitis, and diarrhea.
Use in Special Populations
Pregnancy: Available data from published literature indicate an increased risk of preterm delivery with Atzumi us during pregnancy.
Lactation: Patients should not breastfeed during treatment with Atzumi and for 3 days after the last dose.
Please see the Atzumi Full Prescribing Information, including Boxed Warning and Medication Guide.
The risk information provided here is not comprehensive. The FDA-approved product labeling can be found at www.satsumarx.com. You can also call 1-888-273-2480 for additional information.
About Satsuma Pharmaceuticals
Satsuma Pharmaceuticals Inc., a wholly-owned subsidiary of Shin Nippon Biomedical Laboratories, Ltd. (SNBL), is a late-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. Since its inception in 2016, Satsuma has focused on combining great science, cutting-edge technology and proven drug therapies to create improved therapeutic products that address the significant unmet needs of patients. Satsuma's team has extensive experience successfully developing, manufacturing and commercializing pharmaceutical products within both large and small companies, and we have particular expertise in the area of drug-device combination products delivered via inhalation. For further information, please visit www.satsumarx.com.
About SNBL
Shin Nippon Biomedical Laboratories, Ltd. ('SNBL') (TSE:2395) is a listed nonclinical contract research organization (CRO) that was founded in Kagoshima, Japan, in 1957. Based on its corporate philosophy of 'Committed to the environment, life, and people', and with a proven track record of accomplishment as the oldest and most established Japanese nonclinical CRO, SNBL is proud to offer a comprehensive portfolio of services and solutions for drug discovery and development for pharmaceutical companies, biotech ventures, universities, and research institutions both in Japan and overseas. The SNBL's Translational Research business engages in drug discovery, with the focus on business development and out-licensing of its proprietary intranasal drug delivery technologies and intranasal devices. For further information, please visit https://en.snbl.com/.
Cautionary Note on Forward-Looking Statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Satsuma's future business, future position and results of operations, including estimates, forecasts, targets and plans for Satsuma. Without limitation, forward-looking statements often include words such as 'targets', 'plans', 'believes', 'hopes', 'continues', 'expects', 'aims', 'intends', 'ensures', 'will', 'may', 'should', 'would', 'could' 'anticipates', 'estimates', 'projects' or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding SNBL's business, including uncertainty of commercial success for new and existing products; claims or concerns regarding the safety or efficacy of product candidates; general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; the impact of health crises such as the coronavirus pandemic on Satsuma and its clients and suppliers, including foreign governments in countries in which Satsuma operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Satsuma's operations and the timing of any such divestment(s); and other factors identified in SNBL's most recent securities report ('Yuka Shoken Houkokusho') and SNBL's other reports filed with the Financial Services Agency, available on SNBL's website at: https://en.snbl.com/ir/library or at https://disclosure.edinet-fsa.go.jp/. SNBL does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or related stock exchange rule. Past performance is not an indicator of future results and the results or statements of SNBL in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of SNBL's future results.
Medical Information
This press release contains information about product candidates that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.
Inquiries: Satsuma Pharmaceuticals, Inc.E-mail: info@satsumarx.comWebsite: www.satsumarx.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
21 hours ago
- Malaysian Reserve
Siemba Named a Sample Vendor in Three 2025 Gartner® Hype Cycle™ Reports for the Second Year in a Row
ATLANTA, Aug. 16, 2025 /PRNewswire/ — Siemba, a leading provider of Penetration Testing as a Service (PTaaS) and Continuous Threat Exposure Management (CTEM), announced today that it has been recognized as a Sample Vendor in the 2025 Gartner® Hype Cycle™ for Application Security, Security Operations, and Everything as a Service (XaaS) reports. This marks the second consecutive year Siemba has been included in all three Hype Cycle reports. Siemba believes this reinforces its growing role in shaping the future of offensive security. The Gartner Hype Cycle reports provide a perspective on the maturity and adoption of emerging technologies. For cybersecurity decision-makers, these reports serve as strategic guides to evaluate which innovations can address real-world risks and drive long-term security improvements. In all three reports, Siemba was identified as a Sample Vendor for Penetration Testing as a Service (PTaaS). Siemba believes that its scalable, platform-driven approach to offensive security will make it easier for organizations to secure their data and assets. 'We are proud to be recognized for the second consecutive year across three Gartner Hype Cycle reports. We believe this is a strong validation of our thesis that continuous validation and visibility are critical to modern cybersecurity,' said Kannan Udayarajan, Founder and CEO of Siemba. 'We're proud that our Full Funnel Offensive Security platform is helping organizations find, prioritize, and remediate risks faster—at the pace of their business.' The 2025 Gartner Hype Cycle for Application Security notes: 'Cybersecurity leaders must take advantage of the underlying trends in the application security space to onboard the most appropriate innovations at the optimal time for their organizational maturity.'(Source: Gartner, Hype Cycle for Application Security, 2025. Dionisio Zumerle, 22 July 2025) Gartner states 'PTaaS enables organizations to elevate their security posture with continuous assessments that integrate validation earlier in the software development life cycle as compared with traditional pentesting efforts. It gives access to real-time findings delivered through a platform, which accelerates remediation and improves collaboration efforts.' Siemba's AI driven platform combines External Attack Surface Mapping, Dynamic Application Security Testing (DAST), Automated Vulnerability Assessments, and Penetration Testing as a Service, helping enterprises operationalize CTEM programs at scale. To learn more or download the 2025 Hype Cycle for Security Operations, visit : Gartner Disclaimer Gartner, Hype Cycle for Application Security, 2025, By Dionisio Zumerle, 22 July 2025Gartner, Hype Cycle for Security Operations, 2025, By Jonathan Nunez, Darren Livingstone, 23 June 2025Gartner, Hype Cycle for XaaS, 2025, By Jason Donham, 28 July 2025 GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, HYPE CYCLE is a registered trademark of Gartner, Inc. and/or its affiliates and is used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in our research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. About Siemba Siemba's outcome-driven Full Funnel Offensive Security model brings together Penetration Testing as a Service (PTaaS), Autonomous DAST (Dynamic Application Security Testing), Vulnerability Assessments, and External Attack Surface Mapping on one unified AI-driven platform. The platform delivers actionable data and insights enabling visibility, speed, scalability, and efficiency in Continuous Threat Exposure Management (CTEM). Enterprises, global systems integrators, government agencies and growing companies leverage Siemba to establish CTEM programs, map assets, launch and schedule autonomous assessments, conduct manual penetration testing and autonomously gather strategic threat and efficiency insights to maximize Return on Mitigation, without requiring extensive hacking knowledge or human intervention. The platform provides one-click security-framework-aligned reports, attack scoring, prioritized lists of findings with suggested remediation actions and attack proofs of concept.
Malaysian Reserve
a day ago
- Malaysian Reserve
Novelis Announces Results of Tender Offer for 3.250% Senior Notes due November 2026
ATLANTA, Aug. 15, 2025 /PRNewswire/ — Novelis Inc. (the 'Company') announced today the results of its indirect wholly-owned subsidiary, Novelis Corporation's (the 'Issuer') previously announced cash tender offer for any and all of its 3.250% Senior Notes due November 2026 (the 'Notes'), upon the terms and conditions included in the Offer to Purchase, dated August 11, 2025. As of the expiration time of the tender offer, which was 5:00 pm., New York City time, on August 15, 2025 (the 'Expiration Time'), the aggregate principal amount of the Notes that have been validly tendered and not validly withdrawn was $738,116,000, representing 98.4% of the $750,000,000 aggregate outstanding principal amount of the Notes, which amount includes $2,326,000 that remain subject to the applicable guaranteed delivery procedures. Holders who indicated by the Expiration Time that they will deliver their Notes through the guaranteed delivery procedures set forth in the Offer to Purchase must deliver their Notes by 5:00 p.m., New York City time, on August 19, 2025. The complete terms and conditions of the Tender Offer were set forth in the Offer to Purchase and the related notice of guaranteed delivery (the 'Notice of Guaranteed Delivery'). Subject to the terms and conditions of the tender offer being satisfied or waived, holders who validly tendered and did not withdraw Notes prior to the Expiration Time will receive the 'Tender Offer Consideration' equal to $997.50 per $1,000 principal amount of Notes. In addition to the Tender Offer Consideration, holders will receive accrued and unpaid interest on the Notes from the most recent payment of semi-annual interest for such Notes preceding the Settlement Date to, but not including, the Settlement Date. The Settlement Date is expected to be August 18, 2025. With respect to the Notes tendered and accepted for purchase, if any, pursuant to the guaranteed delivery procedures described in the Offer to Purchase, the holders of any such Notes will receive payment of the Tender Offer Consideration for such Notes, plus accrued and unpaid interest from the most recent payment of semi-annual interest for such Notes preceding the Settlement Date up to, but not including, the Settlement Date, on the settlement date for any Notes tendered pursuant to a Notice of Guaranteed Delivery, which is expected to be August 20, 2025. All accrued and unpaid interest on the Notes from the most recent payment of semi-annual interest for such Notes up to, but not including, the Settlement Date will cease to accrue on the Settlement Date for all Notes accepted for purchase pursuant to the Tender Offer, including those tendered pursuant to the Notice of Guaranteed Delivery. The Company intends to redeem any Notes that are not purchased in the tender offer in accordance with the indenture governing the Notes as more fully described in the Offer to Purchase. The Company has engaged BNP Paribas Securities Corp. to act as Dealer Manager for the tender offer. Persons with questions regarding the tender offer should contact BNP Paribas Securities Corp. toll-free at (888) 210-4358 or collect at (212) 841-3059. Requests for documents should be directed to D.F. King & Co., Inc., the Tender and Information Agent for the tender offer, at (212) 269-5550 (for banks and brokers) or (800) 967-5071 (for noteholders) or by email at LegalTeamUS@ This press release is for informational purposes only and is not an offer to purchase or a solicitation of an offer to purchase with respect to any of the Notes. The tender offer is being made pursuant to the tender offer documents, including the Offer to Purchase and Notice of Guaranteed Delivery that the Company is distributing to holders of the Notes. The tender offer is not being made to holders of Notes in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities or other laws of such jurisdiction. None of the Company, the Dealer Manager, the Tender and Information Agent or their respective affiliates is making any recommendation as to whether or not holders should tender all or any portion of their Notes in the tender offer. About Novelis Novelis Inc. is driven by its purpose of shaping a sustainable world together. We are a global leader in the production of innovative aluminum products and solutions and the world's largest recycler of aluminum. Our ambition is to be the leading provider of low-carbon, sustainable aluminum solutions and to achieve a fully circular economy by partnering with our suppliers, as well as our customers in the aerospace, automotive, beverage packaging and specialties industries throughout North America, Europe, Asia and South America. Novelis had net sales of $17.1 billion in fiscal year 2025. Novelis is a subsidiary of Hindalco Industries Limited, an industry leader in aluminum and copper, and the metals flagship company of the Aditya Birla Group, a multinational conglomerate based in Mumbai. For more information, visit Forward-Looking Statements Statements made in this news release which describe Novelis' intentions, expectations, beliefs or predictions may be forward-looking within the meaning of securities laws. Forward-looking statements include statements preceded by, followed by, or including the words 'believes,' 'expects,' 'anticipates,' 'plans,' 'estimates,' 'projects,' 'forecasts,' or similar expressions. Examples of forward-looking statements in this news release are statements about the timing and completion of the tender offer. Novelis cautions that, by their nature, forward-looking statements involve risk and uncertainty and Novelis' actual results could differ materially from those expressed or implied in such statements. Novelis does not intend, and Novelis disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Malaysian Reserve
2 days ago
- Malaysian Reserve
Children's Hospital of Philadelphia and Children's Hospital Colorado Researchers Conduct First Prospective Study of Pediatric EoE Patients and Disease Progression
Study found that stiffness of the esophagus could serve as an important biomarker for disease progression and indicate which patients may benefit the most from current therapies PHILADELPHIA, Aug. 15, 2025 /PRNewswire/ — Researchers from Children's Hospital of Philadelphia (CHOP) and Children's Hospital Colorado have found that better control of chronic eosinophilic esophagitis (EoE)-associated inflammation during childhood leads to less stiffening of the esophagus, resulting in fewer disease complications. Using Endoluminal functional imaging (FLIP), the study team suggests this could be a key marker for assessing disease severity and progression. The findings were published online today by the journal Gastroenterology. EoE is a chronic allergic inflammatory disease of the esophagus, the muscular tube that carries food from the throat to the stomach. Children can experience nausea, regurgitation, vomiting, abdominal pain and a burning feeling like acid reflux. They may also have difficulty swallowing and gag frequently. Often, they can experience dysphagia, which is when it feels like something is stuck in their throat. If EoE goes untreated, the esophagus may narrow because of scarring, a phenomenon known as stricture. Chronic EoE-associated inflammation can lead to progressive tissue remodeling and fibrostenosis, or the narrowing of the esophagus. While clinicians recognize the severity of the disease, long-term studies looking at disease progression over time, and the impact of controlling the disease from a young age, is relatively unknown. 'This is the first study to follow kids overtime (with these endoscopic assessments) and evaluate the patients who are at the highest risk of complications,' said co-senior study author Amanda Muir, MD, a pediatric gastroenterologist in the Division of Gastroenterology, Hepatology and Nutrition at CHOP. 'With the recent FDA approval of two medications for EoE, having this data could help identify the patients who could benefit from these therapies the most and observe improvement at a histologic level over time.' Researchers at CHOP and Children's Hospital Colorado launched a longitudinal study to evaluate long-term changes in esophageal distensibility, or the ability of the esophagus to expand, in pediatric patients between the ages of 3 and 18 years old. Symptomatic, endoscopic and histologic data were collected at each visit during the study. A total of 112 patients with EoE were included with a median follow-up time of 11 months, some followed for over 4 years. 'Following children living with EoE over time has given us a clearer picture of how inflammation affects the esophagus and how treating it can improve the esophagus and outcomes for patients,' said Calies Menard-Katcher, MD, co-senior study author and Associate Director of Clinical Research for the Gastrointestinal Eosinophilic Diseases Program at Children's Hospital Colorado. 'It's exciting to see these results confirm what we've suspected in caring for patients — and they may even help us spot those at risk for more severe disease.' The study found that patients with tissue samples showing a response to treatment demonstrated the most improvement in distensibility over time. After adjusting for different factors, the study found that patients with lower esophageal distensibility had increased odds of patient-reported dysphagia, or difficulty swallowing. Patients with fibrostenosis were generally diagnosed at an older age, had the disease for a longer period and showed reduced esophageal distensibility at baseline predicted the need for future dilation in patients with strictures. The authors suggest that further studies that examine the disease from a molecular level could help them understand which patients may be at highest risk of severe disease and could benefit from a variety of treatment strategies. This study was supported by the National Institutes of Health grants R01DK124266-01, K23DK109263 and R21TR003039. Kennedy et al, 'Histologic response is associated with improved esophageal distensibility and symptom burden in pediatric eosinophilic esophagitis.' Gastroenterology. Online August 15, 2025. DOI: 10.1053/ About Children's Hospital of Philadelphia:A non-profit, charitable organization, Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, the hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. The institution has a well-established history of providing advanced pediatric care close to home through its CHOP Care Network, which includes more than 50 primary care practices, specialty care and surgical centers, urgent care centers, and community hospital alliances throughout Pennsylvania and New Jersey. CHOP also operates the Middleman Family Pavilion and its dedicated pediatric emergency department in King of Prussia, the Behavioral Health and Crisis Center (including a 24/7 Crisis Response Center) and the Center for Advanced Behavioral Healthcare, a mental health outpatient facility. Its unique family-centered care and public service programs have brought Children's Hospital of Philadelphia recognition as a leading advocate for children and adolescents. For more information, visit ABOUT CHILDREN'S HOSPITAL COLORADO Children's Hospital Colorado is one of the nation's leading and most expansive nonprofit pediatric healthcare systems with a mission to improve the health of children through patient care, education, research and advocacy. Founded in 1908 and ranked among the best children's hospitals in the nation as recognized by U.S. News & World Report, Children's Colorado has established itself as a pioneer in the discovery of innovative and groundbreaking treatments that are shaping the future of pediatric healthcare worldwide. Children's Colorado offers a full spectrum of family-centered care at its urgent, emergency and specialty care locations throughout Colorado, including an academic medical center on the Anschutz Medical Campus in Aurora, hospitals in Colorado Springs, Highlands Ranch and Broomfield, and outreach clinics across the region. For more information, visit or connect with us on Facebook, Instagram and YouTube. Contact: Ben LeachChildren's Hospital of Philadelphia(609)634-7906leachb@
